Ultragenyx Settles DOJOLVI Patent Suit; Generic Entry Pushed to 2033
RARE is trading near its 52-week low of $12.73 (15% above the low).
Summary
Ultragenyx settled its DOJOLVI patent case with Navinta, delaying generic entry until at least January 2033, but other ANDA challenges to the same product are still pending.
Key Events · Legal and Risk Events · RARE
-
DOJOLVI Patent Suit Settled
On October 19, 2026, Ultragenyx and Baylor Research Institute entered a settlement with Navinta LLC, resolving ANDA patent litigation over DOJOLVI (triheptanoin) oral liquid in the U.S. District Court for the District of New Jersey.
-
Generic Entry Delayed to 2033
Navinta receives a non-exclusive, royalty-free license to market its generic DOJOLVI beginning January 1, 2033, extended to July 1, 2033 if pediatric exclusivity is granted.
-
No Royalty Revenue to Ultragenyx
Because the license is royalty-free, the settlement protects the DOJOLVI franchise from generic competition but generates no licensing income for the company.
-
FTC and DOJ Review Required
As required by law, the settlement agreement will be submitted to the U.S. Federal Trade Commission and the Department of Justice.
Analysis · RARE · Life Sciences
A near-term generic threat to one of Ultragenyx's commercial products has been removed. The company and Baylor Research Institute settled the New Jersey patent litigation with Navinta, which had filed an ANDA seeking to sell a generic version of DOJOLVI. Under the terms, Navinta gets a non-exclusive, royalty-free license to launch starting January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted. That locks in roughly six more years of exclusivity, though the royalty-free terms mean no licensing revenue. The settlement still needs FTC and DOJ review, and Ultragenyx faces similar ANDA litigation from other filers on DOJOLVI that remains unresolved, so the protection is partial rather than complete.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RARE was trading at $14.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $12.73 to $39.89. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.